What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report Abbott Laboratories' financial results for the second quarter of 2023. It officially furnishes the press release containing these results.

Does the filing contain specific Q2 2023 financial figures?

While the 8-K filing itself doesn't list the specific financial figures, it incorporates by reference the press release (Exhibit 99.1) which contains Abbott's detailed Q2 2023 results and non-GAAP financial measures.

What are non-GAAP financial measures and why does Abbott use them?

Non-GAAP financial measures are financial metrics that exclude certain items from GAAP (Generally Accepted Accounting Principles) results. Abbott uses them to adjust for factors it considers unusual or unpredictable, such as acquisition costs, restructuring charges, and recall expenses, believing they provide a clearer picture of ongoing operational performance.

What should investors be cautious about regarding the non-GAAP measures?

Investors should be cautious not to view the non-GAAP measures as a replacement for GAAP financial results. They should consider both GAAP and non-GAAP measures to get a comprehensive understanding of Abbott's financial performance, as advised by the company.

ABT 8-K: Earnings & Results

Summary

Abbott Laboratories (ABT) filed an 8-K on July 20, 2023, to report its second-quarter 2023 financial results. The report primarily furnished a press release detailing the company's performance. Investors should note that Abbott, like many companies, utilizes non-GAAP financial measures to present its results, adjusting for items such as acquisition-related expenses, restructuring costs, voluntary recall expenses, impairment charges, and tax-related adjustments. Management believes these measures offer a clearer view of ongoing operational performance, supplementing the standard GAAP reporting.

Key Highlights

1Abbott Laboratories announced its second-quarter 2023 financial results on July 20, 2023, via an 8-K filing.
2The filing includes a press release (Exhibit 99.1) detailing the company's Q2 2023 performance.
3Abbott utilizes non-GAAP financial measures to provide investors with a view of ongoing operational performance, excluding unusual or unpredictable items.
4Items adjusted for in non-GAAP measures include expenses from acquisitions, restructuring, cost reduction initiatives, voluntary recalls, intangible asset impairments, and various tax benefits/adjustments.
5Management uses these non-GAAP metrics internally to assess business performance.
6Investors are advised to consider these non-GAAP measures alongside, not as a substitute for, GAAP financial measures.
7The filing also contains the cover page XBRL data in an inline XBRL document.

ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 20, 2023)

Summary

Key Highlights

Frequently Asked Questions